Cancer lettersFemaleOvarian NeoplasmsHumansAnimalsDoxorubicin
Nanoformulation of a Pin1 inhibitor potentiates the efficacy of liposomal doxorubicin in second-line therapy for ovarian cancer.
Gloria Saorin, Matteo Mauceri, Isabella Caligiuri, Urska Kamensek, Simona Kranjc Brezar, Giuseppe Corona, Ombretta Repetto, Tiziana Perin, Gabriele Grassi, Carlotta Granchi, Tiziano Tuccinardi, Maja Cemazar, Vincenzo Canzonieri, Muhammad Adeel, Flavio Rizzolio
Published: 202610.1016/j.canlet.2025.218128
Abstract
The second-line therapy for high-grade serous ovarian cancer (HGSOC) patients is generally ineffective. Drug selection is not aimed at improving overall survival, but rather based on residual toxicities, clinical judgment, and patient adherence. Ther…
Preview only. Read the full abstract at the source